PP_1170x120_10-25-21

2022 Biosimilar Report: The U.S. Journey and Path Forward

Cardinal Health predicts 2022 to be turning point for biosimilars in the U.S.

Cardinal Health predicts 2022 to be turning point for biosimilars in the U.S.

DUBLIN, Ohio — Cardinal Health has published its 2022 Biosimilars Report: The U.S. Journey and Path Ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from health care providers, and views from leading physicians and experts on biosimilars. The report delivers robust data and insights

Adheris Health